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Abstract
Background: Sphingosine-1-phosphate (S1P) is a bioactive phospholipid that acts as a signal transducer by binding
to S1P receptors (S1PR) 1 to 5. The S1P/S1PRs pathway has been associated with remodeling and allergic inflammation
in asthma, but the expression pattern of S1PR and its effects on non-immune cells have not been completely clarified.
The aim of this study was to examine the contribution of the signaling of S1P and S1PRs expressed in airway epithelial
cells (ECs) to asthma responses in mice.
Methods: Bronchial asthma was experimentally induced in BALB/c mice by ovalbumin (OVA) sensitization followed by
an OVA inhalation challenge. The effects of S1PR antagonists on the development of asthma were analyzed 24 h after
the OVA challenge.
Results: Immunohistological analysis revealed S1PR1-3 expression on mouse airway ECs. Quantitative real-time
polymerase chain reaction demonstrated that S1P greatly stimulated the induction of CCL3 and TIMP2 mRNA in human
airway ECs, i.e., BEAS-2B cells, in a dose-dependent manner. Pretreatment with the S1PR2 antagonist JTE013 inhibited
the CCL3 gene expression in BEAS-2B cells. Immunohistological analysis also showed that the expression level of CCL3
was attenuated by JTE013 in asthmatic mice. Furthermore, JTE013 as well as anti-CCL3 antibody attenuated allergic
responses. Intratracheal administration of JTE013 also attenuated eosinophilic reactions in bronchoalveolar lavage fluids.
S1P induced transcription factor NFκB activation, while JTE013 greatly reduced the NFκB activation.
Conclusions: JTE013 attenuated allergic airway reactions by regulating CCL3 production from bronchial ECs. The
intratracheal administration of JTE013 may be a promising therapeutic strategy for bronchial asthma.
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Background
Sphingosine-1-phosphate (S1P) is a bioactive phospho-
lipid metabolite [1]. It is produced by most kinds of cells
through phosphorylation by sphingosine kinases (SPHK1
and SPHK2), and it works as a signal transducer of
intracellular and extracellular cell homeostasis and func-
tions, such as cell differentiation, inflammation, and
apoptosis [2]. Outside of the cell, S1P binds to five G-
protein-coupled receptors, i.e., S1P receptors (S1PR) 1
to 5, as a ligand. These receptors are expressed mainly
by inflammatory cells, and they play an important role
in immunity. The individual expression pattern of S1PRs
on each cell creates diverse immunological responses
[3]. However, the expression pattern of S1PR and its ef-
fects on non-immune cells remain unclear. Therefore,
we performed a functional analysis of sphingolipids fo-
cusing on the roles of S1P and S1PRs on non-immune
cells. First, we reported that TGF-β increases SPHK1,
and consequently S1P, which transactivates S1PR2 and
S1PR3 on fibroblasts, and promotes their transformation
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to myofibroblasts through Rho kinase [4, 5]. We further
reported that SPHK1 mediates the transformation of air-
way epithelial cells (ECs) to goblet cells [6]. We also
clarified that the intratracheal administration of N,N-
dimethylsphingosine (DMS), a S1P synthesis inhibitor,
restrained allergic inflammation and remodeling [7].
Thus, S1P and S1PRs play crucial roles in remodeling
and allergic inflammation in asthma.
Bronchial asthma is a cytokine-based inflammatory
dysfunction that involves airway ECs, endothelial cells,
and inflammatory cells, such as Th2-type lymphocytes,
dendritic cells, and mast cells [8]. Healthy airway ECs,
which provide a physical barrier, can keep mast cells in a
quiescent state and inhibit mast cell degranulation [3].
However, damage to airway ECs due to inflammation initi-
ates innate immune responses, and stimulates Th2 re-
sponses by directly attracting and activating immune cells,
such as Th2 cells, eosinophils, and mast cells [9–13].
Clarification of the functions of airway ECs and efforts to
minimize airway EC damage are important for asthma
treatment.
In this study, we investigated the expression of S1PRs
on airway ECs and the function of airway ECs in the sig-
naling pathway of the S1P/S1PRs axis by using an ex-
perimental bronchial asthma mouse model. We used
human bronchial ECs, i.e., BEAS-2B cells, stimulated
with S1P for identifying related cytokines to investigate
the signaling pathway, and to evaluate the potential of
S1PR inhibitors as a remedy for bronchial asthma.
Methods
Reagents
S1P (PeproTech, Rocky Hill, NJ) was used. A S1PR2 an-
tagonist (also known as JTE013; Cayman, Ann Arbor,
MI), and a S1PR3 antagonist (also known as VPC23019;
Calbiochem, Darmstadt, Germany) were purchased.
The antibodies used were anti-S1PR1-5 (Cayman) and
anti-CC chemokine ligand (CCL) 3 (R&D Systems,
Minneapolis, MN).
Animals
Female BALB/c mice were purchased from SLC Japan
(Shizuoka, Japan). All mice were raised in sterile cages,
and were used at 7 to 10 weeks of age. Our studies were
approved by the Institutional Animal Care and Use Com-
mittee (Permit Numbers: P130610-R1, and P150804), and
carried out in accordance with the Kobe University
Animal Experimentation Regulations.
Experimental mouse models
The experimental bronchial asthma model mice were
prepared by sensitization with intraperitoneal (i.p.) injec-
tions of 10 μg of ovalbumin (OVA; Sigma-Aldrich, St.
Louis, MO) and 2 mg of aluminum hydroxide (Sigma-
Aldrich) in 0.5 ml of sterile phosphate-buffered saline
(PBS) on days 0 and 7. Then, on days 21 and 22, the mice
were exposed to aerosolized sterile PBS with or without
1.0 % OVA for 30 min with ultrasonic nebulizer, Omron
NE-U07 (OMRON, Kyoto, Japan) (the aerosolized particle
size ranges 1–8 μm). Mice were sacrificed on day 23 for
all mice experimentations. To prepare JTE013-treated or
anti-CCL3 antibody-treated mice, mice were given
JTE013 (4 mg/kg) or anti-CCL3 antibody (0.15 mg/kg)
via i.p. injection before OVA sensitization on days 21
and 22. In the JTE013 intratracheal administration ex-
periment, mice were intratracheally instilled with 10 μg
of JTE013 or PBS.
Analysis of bronchoalveolar lavage fluids
Bronchoalveolar lavage (BAL) fluids were collected by
lavaging lungs three times with 800 μl of PBS, and sam-
ples were stored at −80 °C after centrifugation. The con-
centrations of interleukin (IL)-4, IL-5, IL-13, and IFN-γ
in the BAL fluids were measured using the Mouse
ELISA Kit (R&D Systems) according to the manufac-
turer’s instructions.
Histology
Lungs were harvested to prepare paraffin-embedded sec-
tions for histological analysis. PBS was perfused through
the lungs of mice under deep anesthesia, and the lungs
were then fixed by intratracheal instillation of phosphate-
buffered paraformaldehyde (Wako, Osaka, Japan). Airway
EC areas were evaluated in five randomly selected sec-
tions, and each section was subjected to hematoxylin and
eosin staining and immunostaining, as previously de-
scribed [14, 15].
Cell culture and stimulation
BEAS-2B cells (ATCC, Manassas, VA) were incubated
with the BEGM Bullet Kit (Lonza, Walkersville, MD)
under a humidified atmosphere containing 5 % CO2 at
37 °C. To analyze the secretion of cytokines, the cells were
stimulated with or without S1P (100 nM or 1 μM) for 3 h.
In other experiments, cells were treated with 1 μM S1P
and 10 μM JTE013, 10 μM VPC23019, 50 μM S3I-201
(STAT3 inhibitor, Cosmo Bio Co, Tokyo, Japan), 2.9 μM
IKK inhibitor III (Calbiochem), or dimethyl sulfoxide
(DMSO).
Quantitative real-time polymerase chain reaction analysis
Total cellular RNA was prepared and quantitative real-
time polymerase chain reaction (qRT-PCR) was per-
formed as previously described [16]. Relative human
mRNA levels were calculated with the ΔΔCt method
using glyceraldehyde-3-phosphate dehydrogenase mRNA
as an internal control. The sequences of the sense and
antisense primers are listed in Additional file 1: Table S1.
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Western blotting analysis
The preparation of cell lysates, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, and immunoblotting
were performed as previously described [17]. Primary
antibodies against NFκB (Santa Cruz Biotechnology,
Dallas, TX) and β-actin (Cell Signaling, Danvers, MA),
and secondary antibodies (Cell Signaling) were used.
Statistical analysis
Data are shown as the mean ± standard error of the
mean (SEM). Statistical analyses were performed using
the Student’s unpaired t-test to compare two groups.
The significances of all statistical tests are provided in
the figures. A p-value of <0.05 was considered to be sta-
tistically significant.
Results
S1PR1-3 is expressed on airway epithelial cells in vivo
Previous studies suggested the existence of S1PRs on air-
way ECs, because the administration of DMS to ECs
mitigated allergic reactions [6, 7]. Thus, we investigated
the localization of S1PRs on ECs by immunostaining
with S1PRs antibodies. As shown in Fig. 1, S1PR1,
S1PR2, and S1PR3 were expressed in airway ECs, includ-
ing bronchial ECs and alveolar ECs. These results sug-
gest that the S1P/S1PR1-3 axis in airway ECs has a
possible role in airway inflammation.
S1P stimulation of airway ECs evidently induces CCL3 and
TIMP2 gene expression in vitro
Next, we analyzed the function of the S1P/S1PR1-3 axis
in cytokine secretion by using BEAS-2B human airway
ECs. Comparison by qRT-PCR of the cytokine mRNA
levels of S1P- or DMSO-treated BEAS-2B cells indicated
that stimulation with S1P promoted the expression of
CCL3 and TIMP2 (Fig. 2a).
CCL3 and TIMP2 are S1P-dependent in vitro and in vivo
We further analyzed the dose-dependent CCL3 and
TIMP2 gene expression in BEAS-2B cells after stimula-
tion with S1P. As shown in Fig. 2b, CCL3 and TIMP2
gene expression in BEAS-2B cells increased in propor-
tion to the S1P concentration, and they were attenuated
by JTE013, a S1PR2 antagonist (Fig. 2c). In contrast, nei-
ther was attenuated by VPC23019, a S1PR1 and S1PR3
antagonist (Fig. 2c). Immunohistological analysis also
showed that CCL3 and S1PR2 were co-expressed on the
airway ECs in the experimental asthma mouse model,
and the expression level of CCL3 was attenuated by
JTE013, although the expression level of S1PR2 was not
attenuated by JTE013 because JTE013 only inhibits S1P
binding to S1PR2 (Fig. 3a). further analyzed the effect of
CCL3 on airway allergic response using the experimental
asthma mouse model. As shown in Fig. 3b, airway
eosinophilia and the levels of IL-4, IL-5, and IL-13 were
attenuated by the anti-CCL3 antibody. These results
suggest that S1P induced the secretion of CCL3, which
has a crucial role in bronchial asthma through the S1P/
S1PR2 axis in airway ECs.
JTE013 decreases allergic responses
To investigate the effects of the S1P/S1PR2 axis on
bronchial asthma, we employed an experimental asthma
mouse model and evaluated the therapeutic effects of
JTE013. As expected, OVA-treated mice showed a
marked increase in the number of eosinophils in the
BAL fluids (Fig. 4a). In addition, the levels of IL-4, IL-5,
and IL-13 were increased in the BAL fluids from OVA-
treated mice (Fig. 4b). In contrast, JTE013 administration
resulted in a significant decrease in Th2 inflammatory re-
actions, although there was no statistical difference in the
levels of IL-4 (Fig. 4a and b). Consistent with the BAL
fluids analysis, histological analysis demonstrated a





Fig. 1 S1PR1-3 is expressed on airway epithelial cells in vivo. Lung
sections from BALB/c mice immunostained with antibodies against
S1PR1-5 and without these antibodies (control IgG). Bronchial ECs
are stained with S1PR1-3 antibodies (arrows), and alveolar ECs are
stained with S1PR2 and 3 antibodies (arrowheaads)
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Fig. 2 S1P stimulation of airway ECs induces CCL3 and TIMP2 gene expression, and CCL3 and TIMP2 are S1P-dependent in vitro. BEAS-2B cells
were cultured with or without S1P (100 nM). The mRNA expression of 29 cytokines was analyzed by quantitative real-time RT-PCR. Data represent
the ratio between the relative mRNA level of S1P-treated cells and that of S1P-untreated cells (a). BEAS-2B cells were treated with S1P (100 nM or
1 μM) (b), S1P (1 μM) and JTE013 (10 μM), or S1P (1 μM) and VPC23019 (10 μM) (c) for 3 h, and CCL3 and TIMP2 gene expression was analyzed
by quantitative real-time RT-PCR
Fig. 3 CCL3 and TIMP2 are S1P-dependent in vivo. Immunofluorescent microscopic images show OVA-treated lung sections stained with FITC-
conjugated anti-CCL3 (green), and Alexa 594-conjugated anti-S1PR2 (red) antibodies. Co-localization of CCL3 and S1PR2 is seen in yellow (a). BAL Fluids
were obtained from BALB/c mice treated with vehicle, OVA, or OVA/mCCL3 antibody (3 μg/cavity), and examined by Diff-Quick staining. The total cell
counts and cell differentials in the BAL fluids are shown, and the concentrations of IL-4, IL-5, and IL-13 in the BAL fluids were measured by using ELISA
kits (b). Data are expressed as the mean ± standard error (SE) of at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
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the bronchiole in OVA/JTE013-treated mice when com-
pared to OVA-treated mice (Fig. 4c).
Moreover, intratracheal administration of JTE013 also
resulted in a marked decrease in eosinophilic reactions
in the BAL fluids (Fig. 4d). This suggests that intratra-
cheal treatment can inhibit allergic bronchial inflamma-
tion as well as i.p. treatment.
JTE013 inhibits CCL3 gene expression by attenuating
NFκB and STAT3 activation in vitro
Next, we analyzed the signaling pathways downstream of
S1PR2, and investigated the activation of transcription fac-
tors, NFκB and STAT3. Previous study reported that
S1PR2 can activate the transcription factor, STAT3 in
mice lung [18], which regulates CCL3 expression in
macrophage [19], and the transcription factor NFκB also
induces CCL3 synthesis in nucleus pulposus cells [20]. In
this study, using BEAS-2B cells, we first assessed the activ-
ity of NFκB downstream of the S1P/S1PR2 signaling path-
way, and next analyzed the CCL3 expression downstream
of NFκB and STAT3 activation. The results are shown in
Fig. 4e and f. The expression of NFκB increased after
stimulation with S1P, while it decreased with JTE013
(Fig. 4e), and CCL3 gene expression in BEAS-2B cells in-
creased with the S1P concentration, while it was attenu-
ated by IKK inhibitor, and a STAT3 inhibitor, S3I-201.
Taken together, these results suggest that JTE013 inhibits
CCL3 expression through NFκB and STAT3 transcription.
Discussion
The aim of this study was to elucidate the role of S1P in
bronchial asthma by focusing on airway ECs. Patho-
logical analysis showed that S1PR1-3 are expressed on
airway ECs, and airway ECs that expressed S1PR2 also
expressed CCL3 at a high level in response to the OVA
inhalation challenge. Our previous research showed the
inflammation induced by OVA exposure decreases in
time-dependent manner [17]. Therefore, we adopted our
time schedule as appropriate duration time.
In vitro analysis of cytokine expression in human
bronchial ECs also showed that S1P led to the transcrip-
tional activation of the CCL3 gene through NFκB and
Fig. 4 JTE013 decreases allergic responses. BAL fluids were obtained after OVA or vehicle exposure, and examined by Diff-Quick staining. Total cell
counts and cell differentials in the BAL fluids are shown (a), and the concentrations of IL-4, IL-5, IL-13, and IFN-γ in the BAL fluids were measured
by using ELISA kits (n = 5) (b). Lung sections from BALB/c mice treated with vehicle, OVA, or OVA/JTE013 (4 mg/kg) were subjected to hematoxylin
and eosin staining (c). BAL fluids were obtained after OVA or vehicle exposure with intratracheal administration of vehicle or JTE013 (10 μg/trachea),
and the total cell counts and cell differentials in the BAL fluids were examined by Diff-Quick staining (n = 3 to 5) (d). BEAS-2B cells were treated with
vehicle, S1P (1 μM), or S1P/JTE013 (1 μM) for 4 h. Phosphorylation of p65 was evaluated by western blot analysis. Representative images from three
independent experiments are shown (e). BEAS-2B cells were treated with vehicle, S1P (1 μM), IKK inhibitor, or S3I-201. Each CCL3 gene expression was
analyzed by quantitative real-time RT-PCR, representing the relative mRNA level of CCL3 (f). Data are expressed as the mean ± SE of at least three
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
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STAT3 activation. Previous studies reported that S1PR2
is coupled to GαI, Gα12/13, and GαQ, which activates
phospholipase C (PLC) [21, 22]. PLC plays a role in the
regulation of intracellular signaling pathways through
calcium release and protein kinase C activation [22].
PLC also plays a role in proinflammatory gene expression
through the activation of NFκB [23]. These results suggest
that the S1P/S1PR2 axis has a possible role in cytokine ex-
pression via the activation of NFκB downstream of PLC.
Furthermore, STAT3 is directly activated by S1PR2 in a
Rho-dependent manner [18, 24], which is dependent on
the S1PR2-coupled G protein Gα12/13 [21].
We used human bronchial ECs instead of mouse
bronchial ECs as previous literatures [25–27], because
previous reports showed that approximately 99 % of
mouse genes have a homologue in the human genome
[28], and bioinformatic analysis and human curation of
60,770 full-length mouse cDNA clones showed similarity
(70–85 % identity) to known human-disease genes [29].
CCL3 expression is up-regulated by NFκB and STAT3.
Consistent with our results, Jianru W et al. also demon-
strated that NFκB introduces CCL3 synthesis, by binding to
the proximal promotor of CCL3 major nuclear proteins in
nucleus pulposus cells [20]. Furthermore, Zhang C et al.
also reported that STAT3 is a key regulator of CCL3 ex-
pression in macrophages [19]. Taken together, we infer that
the S1P/S1PR2 axis activates STAT3 and NFκB to form a
complex with CCL3 nuclear protein binding sites, which in
turn produces CCL3 through Gα12/13 and GαQ (Fig. 5).
CCL3 is a member of the C-C chemokine family, and is
a chemoattractant for eosinophils, lymphocytes,
leukocytes, and monocytes. Previous studies reported that
an increased level of CCL3 was observed in BAL fluids
from patients with asthma [30], and that CCL3 evoked
local T cell recruitment and induced skin reactions in pa-
tients with atopic dermatitis [31]. Furthermore, Elena et
al. demonstrated significantly higher levels of CCL3 in
BAL fluids from patients with corticosteroid-resistant
asthma [32].
CCL3 is also a ligand for CCR1 and CCR4. CCR1 is
expressed in mast cells and basophils, and the CCL3/
CCR1 axis is important for the activation of mast cells
[33]. A previous study reported that CCL3 acted as a co-
stimulator for FcεRI-mediated degranulation in conjunc-
tival mast cells in CCL3-deficient mice [34]. Moreover,
CCL3 synergistically enhanced FcεRI-mediated degranula-
tion and the production of CCL2, which is a chemo-
attractant for T cells and eosinophils in bone marrow-
derived murine mast cells and the rat basophilic leukemia
2H3 cell line [33, 35–39]. Taken together, there is crosstalk
between CCR1-mediated and FcεRI-mediated signaling
cascades in mast cells, which plays an important role in al-
lergic disorders as FcεRI cross-linking is a key event of ac-
tivation. On the other hand, CCR4 mediates allergy-
promoting Th2 cell recruitment [23]. A recent publication
by Oskeritzian et al. demonstrated that S1P neutralization
or a S1PR2 antagonist strongly attenuated early T-cell re-
cruitment to lung perivascular lesions and T-cell chemo-
kine production, including CCL3, in murine mast cell-
dependent acute airway allergic responses [23], suggesting
that the S1P/S1PR2 axis regulates early T-cell recruitment
via chemokine production. In our study, immunohisto-
chemical analysis showed that CCL3 was abundantly pro-
duced by airway ECs. Therefore, CCL3 on airway ECs
may be a promising target for the treatment of airway al-
lergic inflammation, which is mediated by T-cell recruit-
ment. In fact, our study showed that CCL3 neutralization
actually reduced Th2-type allergic responses.
The importance of S1P in an experimental asthma mouse
model is well established [4–7]. Past reports have suggested
that the S1P/S1PR2 axis also plays an important role in
antigen-induced mast cell degranulation [40], myofibroblast
contraction [41], and vasoconstriction [42]. Our study first
verified the contribution of the signaling of the S1P/S1PR2
axis in airway ECs. However, the intraperitoneal administra-
tion of S1PR2 antagonist to investigate the in vivo reaction
of airway ECs can also induce a systemic reaction, as de-
scribed above. Although we examined the intratracheal ad-
ministration of a S1PR2 antagonist, the possibility cannot
be excluded that the method could also induce systemic re-
action through resident mast cells around airway ECs. In
order to determine the effects of the S1PR2 antagonist on
airway ECs in vivo, an appropriate experimental mouse
model, such as S1PR2-deficient mice [43], should be
employed.
Fig. 5 Simplified scheme of the S1PR2 signaling events in airway
epithelial cells. On airway epithelial cells, S1P binds to S1PR2, which
is coupled to GaI, Ga12/13, and GaQ. GaQ in turn activates PLC,
activating PKC. PKC phosphorylates NFκB, which binds to the
proximal promotor of CCL3 major nuclear proteins. In addition,
another S1PR2-coupled G protein, Ga12/13, also up-regulates CCL3
expression through STAT3 activation in a Rho-dependent manner
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Our in vitro study using primary cultures demonstrated
that the S1P/S1PR2 axis promotes airway inflammation.
Intriguingly, Yapeng et al. showed that S1PR2 induced the
extrusion of apoptotic kidney ECs to maintain an intact
barrier [44]. In addition, Kono et al. showed that S1PR2-
knockout mice had defective epithelial barrier function in
the cochlea [45]. These results suggest that inhibition of
the S1P/S1PR2 pathway disturbs the barrier function of
ECs, and may aggravate asthmatic reactions. We have two
hypotheses to account for these contradictory findings.
One hypothesis is that the nature of airway ECs is differ-
ent from those of other ECs. The other hypothesis is that
the quantity of JTE013 used was enough to restrain in-
flammatory responses, but not enough to restrain the ex-
trusion of airway ECs. Further studies investigating the
effects of the S1PR2 antagonist at different intratracheal
dosage levels on asthma would be of great interest.
In addition, we investigated the allergic reaction by
intratrachial administration of aerosolized OVA and
JTE013 to show the potential of intratrachial administra-
tion of JTE013 as the remedy of bronchial asthma. How-
ever, Kannan et al. have revealed that the deposition of
particle substance to airway and lung depends on many
factors including the property of the particle, anatomical
geometry of the airway, and respiratory pattern [46, 47].
And it may be possible to obtain more analysis from the
computational Euler-Langrangian particle delivery ap-
proach of Kannan et al. [47]. In this point, there are
some limitations to interpret our in vivo data. Though
extrapolating from our studies with intratrachial admin-
istration in mouse model to the allergic reaction in
humans requires cautious interpretation, our data can
provide significant promise to JTE013 as the remedy be-
cause previous study showed that asthma mouse model
can be used to investigate the main point of our patho-
genesis, allergic reaction through the cytokine produc-
tion [48] and previous report showed the intratrachial
administration of drugs such as budesonide in mice has
similar efficacy in humans [49]. Therefore, I think our
results can lead to the development of worthwhile thera-
peutic interventions.
Conclusion
This study demonstrated that the S1PR2 antagonist
JTE013 inhibits asthmatic allergic reactions by suppress-
ing the S1PR2-mediated NFκB activation and CCL3 pro-
duction in the bronchial epthelium, and that the
intratracheal administration of JTE013 may be a promis-
ing remedy for bronchial asthma.
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